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Background: Oral squamous cell carcinomas are often heavily infiltrated by immune cells. The organization of B-cells,
follicular dendritic cells, T-cells and high-endothelial venules into structures termed tertiary lymphoid structures have been
detected in various types of cancer, where their presence is found to predict favourable outcome. The purpose of the
present study was to evaluate the incidence of tertiary lymphoid structures in oral squamous cell carcinomas, and if
present, analyse whether they were associated with clinical outcome.
Methods: Tumour samples from 80 patients with oral squamous cell carcinoma were immunohistochemically stained for
B-cells, follicular dendritic cells, T-cells, germinal centre B-cells and high-endothelial venules. Some samples were sectioned
at multiple levels to assess whether the presence of tertiary lymphoid structures varied within the tumour.
Results: Tumour-associated tertiary lymphoid structures were detected in 21 % of the tumours and were associated with
lower disease-specific death. The presence of tertiary lymphoid structures varied within different levels of a tissue block.
Conclusions: Tertiary lymphoid structure formation was found to be a positive prognostic factor for patients with oral
squamous cell carcinoma. Increased knowledge about tertiary lymphoid structure formation in oral squamous cell
carcinoma might help to develop and guide immune-modulatory cancer treatments.
Keywords: Oral squamous cell carcinoma, Prognostic factor, Tertiary lymphoid structure, B-cell, High-endothelial venule,
Follicular dendritic cell, Germinal centreBackground
Oral squamous cell carcinomas (OSCCs) are tumours
known to metastasize to lymph nodes at an early stage
of their development [1]. Despite current improvements
in clinical management of this cancer type, mortality
and morbidity rates of OSCC patients have remained
high over the last decades, with an average 5-year survival
rate of about 50% [2,3]. The TNM staging of the tumour,
and especially the presence and extent of lymph node me-
tastasis (N stage), have considerable prognostic importance
for patients with OSCC [4] and are used to guide treatment
strategies. However, tumours of the same clinical stage may
respond differently to the same treatment and may also
have distinct clinical outcomes [5].* Correspondence: elin.hadler-olsen@uit.no
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unless otherwise stated.Considerable interest has been devoted to the complex
interplay between tumour cells and host-immune re-
sponse, and especially to how infiltrating immune cells
might affect the clinical outcome of cancer patients. Anti-
tumour functions of tumour-infiltrating lymphocytes
(TILs), particularly of T-cells, have been observed in nu-
merous types of cancer [6]. Accumulating evidence indi-
cates that infiltrating immune cells may also be involved
in the development and progression of oral cancer, where
they have shown both favourable and detrimental effects
[7]. It is well established that immune cells infiltrating to
sites of chronic inflammation organize themselves both
anatomically and functionally similar to secondary lymph-
oid organs (SLOs), a phenomenon called tertiary lymphoid
structure (TLS) formation [8]. Similar to lymphoid folli-
cles, TLSs typically comprise aggregates of B-cells in a
meshwork of follicular dendritic cells (FDCs) that are then
surrounded by T-cells as well as specialized blood vesselsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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express the lymphoid chemokine peripheral node addres-
sin (PNAd), which binds to L-Selectin on naive lympho-
cytes and thus promote lymphocyte recruitment to sites
of chronic inflammation [10]. Furthermore, a complex
interplay between different lymphotoxin- and chemokine-
induced signalling pathways is required for the initiation
of TLS formation [9]. In contrast to lymph nodes, TLSs
are not encapsulated, resulting in constitutive, direct anti-
genic stimulation from their surrounding microenviron-
ment [11]. Lymphatic vessels have also been found in
association with TLSs, but their functional interplay is not
yet fully clarified [12]. The presence of ongoing germinal
centre (GC) reactions in B-cell clusters of ectopic lymph-
oid structures has been reported, indicating that adaptive
immunity can be triggered at sites different from SLOs
[11]. In autoimmune disorders, formation of ectopic
lymphoid tissue is associated with disease progression
[11], whereas TLS development in breast, ovarian, non-
small-cell lung, renal and colorectal cancer is reported to
be associated with a favourable prognosis [13-23].
The aim of the present study was to evaluate the inci-
dence of TLSs in OSCCs, and if present, analyse whether
they were associated with clinical outcome. The study
included tissue samples and clinical data from 80 pa-
tients diagnosed with OSCCs between 1986 and 2002 at
the Diagnostic Clinic – Clinical Pathology, University
Hospital of North Norway (UNN). The presence of TLSs
was determined based on immunohistochemical staining
patterns of B-cells, FDCs, GC B-cells, T-cells and HEVs.
We established that the presence of TLSs is a positive
prognostic factor for patients with OSCC. Understand-
ing and interpreting TLS formation in OSCC might
help to implement and guide immunotherapeutic inter-
ventions. In terms of individual clinical management,
reliable prognostic markers together with targeted anti-
cancer therapies might improve the consistently low
survival rates in patients with oral cancer.
Methods
Patients
The study broadly follows the REMARK recommenda-
tions for tumour marker prognostic studies [24]. Eighty
patients with histologically verified primary SCC of the
oral cavity in the period 1986–2002 were selected from
the archives of the Diagnostic Clinic – Clinical Pathology,
UNN. The last day of follow-up was January 1st, 2012. The
specimens were formalin-fixed, paraffin-embedded tumour
resections or biopsies from the mobile tongue, floor of the
mouth, buccal mucosa, gingiva and soft and hard palate.
We excluded specimens from the base of the tongue and
the tonsils – sites naturally rich in lymphatic tissue. Patients
with a history of former head and neck cancer were also ex-
cluded from the study. Clinical data, including tumourstaging according to the TNM-classification and treatment
modalities, were retrieved from the patients’ hospital files,
pathology reports and the Statistics of Norway, Cause of
Death Registry, and are listed in Table 1. Information on
the HPV status determined by p16 immunohistochemical
staining was obtained from the Diagnostic Clinic – Clinical
Pathology, UNN, and is also presented in Table 1. In
addition to the patient samples, formalin-fixed, paraffin-
embedded normal oral tissue was used as control. The
study was approved by the Regional Committee for Medical
and Health Research Ethics, Northern Norway (REK-num-
ber 22/2007), which also gave the permission to access pa-
tient files containing the clinical data. All clinical data were
kept anonymous.
Immunohistochemistry
Four-micrometer-thick sections of formalin-fixed, paraffin-
embedded tissue of patients with OSCC on Superfrost Plus
slides were subjected to immunohistochemical staining.
From patients where several tumour-containing paraffin-
blocks were available, a block with representative material,
based on H/E staining, was chosen without specific evalu-
ation of the inflammatory infiltrate. Before staining, all
specimens were incubated overnight at 60°C, deparaffinised
in xylene, rehydrated in graded alcohol baths and subjected
to heat-induced antigen retrieval in 0.01 M sodium citrate
buffer at pH 6.0. Prior to antibody incubation, inherent
peroxidase activity in the tissue was blocked with 3%
H2O2 (Ventana Medical Systems, France or Dako
Glostrup, Denmark). The following primary antibodies
were used: Mouse anti-CD20, clone L26; Mouse anti-
CD21, clone 2G9; Mouse anti-bcl-6, clone GI191E/A8;
Mouse anit-CD34, clone QBEnd/10; Rabbit anti-CD3,
clone 2GV6 (all from Ventana Medical Systems, France);
Mouse anti-Podoplanin, clone D2-40 (Dako, Glostrup,
Denmark) and Rat anti-PNAd, clone MECA-79, (Biolegend,
San Diego). Dilutions and incubation times are listed in
Table 2. Except for the PNAd antibody, all immunohisto-
chemical stainings were done in the automated slide stainer
Ventana Benchmark, XT (Ventana) at the Diagnostic
Clinic – Clinical Pathology, UNN, which is accredited ac-
cording to the ISO/IEC 15189 standard for the respective
stainings, using the same protocols, positive and negative
controls as in the clinical routines. For these automated
stainings, a cocktail of HRP labelled goat anti-mouse
IgG/IgM and mouse anti-rabbit secondary antibodies
together with diaminobenzidine from the Ventana
UltraView Universal DAB Detection Kit (#760-500,
Ventana) were applied for visualization.
Manual staining with the PNAd primary antibody
was performed as previously described [25], using
HRP-labelled goat anti-rat light chain secondary anti-
body (#AP202P, Millipore, Temecula, CA) and diamino-
benzidine (Dako EnVision + System-Horseradish Peroxidase,
Table 1 Comparison of clinicopathological variables












Male 35 (55.6) 11 (64.7) 0.498
Female 28 (44.4) 6 (35.3)
Age at diagnosis, years
Mean 63.19 63.71 0.178
0-59 23 (36.5) 6 (35.3) 0.926
≥ 60 40 (63.5) 11 (64.7)
Smoking history
Never smoker 14 (22.2) 4 (23.5)
Former smoker 10 (15.9) 1 (5.9) 0.722
Current smoker 34 (54.0) 11 (64.7)
Unknown 5 (7.9) 1 (5.9)
Alcohol consumption
Never 12 (19.0) 1 (5.9)
≤ 1 times weekly 24 (38.1) 6 (35.3) 0.114
> 1 times weekly or daily 17 (27.0) 3 (17.6)
Unknown 10 (15.9) 7 (41.2)
Tumour site
Mobile tongue 29 (46.0) 9 (52.9)
Floor of mouth 17 (27.0) 5 (29.4)
Soft palate 1 (1.6) 0 (0.0) 0.956
Buccal mucosa 7 (11.1) 1 (5.9)
Alveolar ridge 8 (12.7) 2 (11.8)
Unknown 1 (1.6) 0 (0.0)
Tumour differentiation
Well 20 (31.7) 10 (58.8)
Moderate 39 (61.9) 5 (29.4) 0.058
Poor 4 (6.3) 2 (11.8)
T stage
T1 23 (36.5) 6 (35.3)
T2 18 (28.6) 9 (52.9) 0.187
T3, T4 21 (33.3) 2 (11.8)
Unknown 1 (1.6) 0 (0.0)
N stage
N0 41 (65.1) 13 (76.5)
0.670
N+ 17 (27.0) 3 (17.6)
Unknown 5 (7.9) 1 (5.9)
M stage
M0 57 (90.5) 17 (100.0)
Table 1 Comparison of clinicopathological variables
between 80 OSCC patients with and without TLSs using
Pearson’s Chi-square test (Continued)
M+ 1 (1.6) 0 (0.0) 0.417
Unknown 5 (7.9) 0 (0.0)
Treatment
Surgery local +/− neck resection 7 (11.1) 2(11.8)
Surgery and radiotherapy 41 (65.1) 12 (70.6)
Radiotherapy +/−
chemotherapy
8 (12.7) 3 (17.6) 0.700
None or palliative 5 (7.9) 0 (0.0)
Unknown 2 (3.2) 0 (0.0)
HPV/p16
Negative 52 (82.5) 16 (94.1)
Positive 5 (7.9) 1 (5.9) 0.386
Unknown 6 (9.5) 0 (0.0)
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Harris hematoxylin (Sigma-Aldrich, St. Louis, MO). Fi-
nally, the sections were dehydrated in graded alcohol
and xylene baths, and mounted with Histokit (Chemi-
teknikk, Oslo, Norway). Negative controls were treated
identically but with the primary antibodies replaced by
the antibody diluting solution. Formalin-fixed, paraffin-
embedded human lymph nodes served as positive con-
trols for the PNAd staining. Negative control sections
never showed any staining, whereas the positive control
sections (lymph nodes) always showed positive staining
confined to the cells that were supposed to be positive
(data not shown). The specificity of the PNAd antibody
was evaluated on consecutive sections from six different
OSCC samples and three samples of normal oral mucosa.
These OSCC and normal tissue sections were assessed forTable 2 Antibodies for immunohistochemistry
Antibody Dilution Incubation
time
Mouse anti-CD20, clone L26,
Ventana Medical Systems, France
Pre-diluted 16 min
Mouse anti-CD21, clone 2G9,
Ventana
Pre-diluted 32 min
Mouse anti-bcl-6, clone GI191E/A8,
Ventana
Pre-diluted 40 min
Mouse anti-Podoplanin, clone D2-40,
Dako, Glostrup, Denmark
1:25 32 min
Mouse anit-CD34, clone QBEnd/10,
Ventana
Pre-diluted 32 min
Rabbit anti-CD3, clone 2GV6, Ventana Pre-diluted 16 min
Rat anti-PNAd, clone MECA-79,
Biolegend, San Diego
1:25 30 min
Goat anti-rat light chain antibody,
#AP202P, Millipore, Temecula, CA
1:250 30 min
Wirsing et al. BMC Clinical Pathology 2014, 14:38 Page 4 of 10
http://www.biomedcentral.com/1472-6890/14/38overlapping immunohistochemical staining for the PNAd
antibody, the blood vessel marker CD34 and the lymphatic
endothelial cell marker D2-40. In the OSCC samples, spor-
adic CD34+ blood vessels were to a minor degree positive
for PNAd, whereas no D2-40+ lymphatic vessels were posi-
tive, indicating a high degree of antibody specificity. No
HEV staining was seen in the three samples from normal
oral mucosa.Immunohistochemical evaluation
Eighty patients were included in the study. In 25 of the pa-
tients, the presence of TLSs was evaluated at a single level
in the tumour tissue block. In 45 of the patients – ran-
domly chosen from the 80 patients – TLS formation was
evaluated at two discrete levels at about 100 μm distance in
the tissue block. Additionally, tumour tissue blocks from 10
of the patients – nine of them negative for TLSs in the
superficial level – were cut down completely and presence
of TLSs was evaluated at 100 μm distance throughout the
tumour sample.
We used a two-step method for TLS detection. First,
the tissue sections were immunohistochemically stained
for the pan B-cell marker CD20 and assigned to three
different groups based on their staining pattern: obvious
B-cell aggregates, indistinct aggregates of B-cells and
no or scattered B-cells. Second, staining for the FDC
marker CD21, the T-cell marker CD3 and the HEV
marker PNAd was performed on consecutive sections of
those with obvious and indistinct B-cell aggregates. For
FDC evaluation, areas with clusters of B-cells were exam-
ined at high-power magnification (400×). All tumours that
had one or several accumulations of B-cells containing
CD21 positive FDCs were defined as TLS-positive. All
TLSs also contained HEVs and T-cells. The TLS-positive
tumours were further subdivided into classical and non-
classical TLSs. A classical TLS was defined as a B-cell ag-
gregate containing a continuous FDC meshwork, and a
non-classical TLS as a B-cell aggregate with a more diffuse
distribution of the FDCs. Sections from seven of the TLS-
positive tumours were stained with BCL-6 to verify the
presence of GC B-cells in B-cell clusters of TLSs.Statistical analysis
All statistical analyses were performed with the SPSS
software version 22.0 for Windows (IBM, Armonk,
NY). The association between various clinicopathological
variables was examined by the Pearson’s Chi-square test.
Disease-specific death (DSD) and disease-specific survival
(DSS) curves were estimated in univariate analyses and by
Kaplan Meier method. The log-rank test was used to
evaluate significant differences between the groups of
patients. Variables that were statistically significant in the
univariate analysis were entered into multivariate Coxregression analyses to identify independent prognostic
factors in the presence of other variables. Validity of
the proportionality assumption was verified by plotting
log-minus-log plots. P-values less than 0.05 were con-
sidered statistically significant.
Results
Presence of TLSs in OSCC
TLSs are highly organized structures that typically ap-
pear as clusters of B-cells containing FDCs. These clus-
ters are then surrounded by T-cells and HEVs as shown
schematically in Figure 1. We investigated the presence
of TLSs in tumour specimens from 80 patients with
OSCCs using immunohistochemistry. Sections with dis-
tinct or more diffuse B-cell aggregates were considered
likely to have TLSs, and their consecutive sections were
stained for FDCs, T-cells and HEVs, whereas sections
without B-cell aggregates were not further analysed. At
the first level assessed, TLSs were found in 13 of the 80
specimens. Eleven of these TLSs were found in sections
with distinct B-cell aggregates, and only two in sections
with diffuse B-cell aggregates. Pictures of a classical TLS
are shown in Figure 2. One more TLS-positive tumour was
identified by staining for TLSs at an additional level about
100 μm deeper in the tissue blocks from 45 of the patients.
Three additional TLS-positive tumours were detected by
assessing the whole tissue sample from 10 patients. These
three TLS-positive tumours showed TLSs at multiple levels.
Altogether, TLSs were found in 17 (21 %) of the 80 patients
included in the study. The maximum number of TLSs in a
single section was four, but usually not more than two TLSs
were detected in each of the positive sections. The TLSs
were mainly found in the peri-tumoural stroma within
0.5 mm distance from the tumour front, in lymphocyte-
rich subepithelial areas.
Within the B-cell aggregates, FDCs were found in either
of two patterns: distinct meshworks (Figure 3A) or diffuse
accumulations (Figure 3B) of CD21 positive cells. Only B-
cell aggregates with contiguous FDC meshworks showed
distinct accumulations of BCL6+ GC B-cells (Figure 3C)
and are here referred to as classical TLSs. In the B-cell ag-
gregates with diffuse accumulations of FDCs, GC B-cells
were either absent (Figure 3D) or dispersed throughout the
follicle, and these are here referred to as non-classical TLSs.
Sometimes both classical and non-classical TLSs were
found in the same section. Analyses of multiple tissue levels
showed that some TLSs classified as non-classical on one
tissue level presented a classical pattern on another tissue
level and vice versa.
Clinicopathological characteristics and prognostic value
of TLSs
Clinicopathological data of the patients were analysed
for correlation with the presence of TLSs, and the
Figure 1 Schematic model of tertiary lymphoid structures. Specialized cell populations arrange themselves into distinct patterns forming a
classical tertiary lymphoid structure (TLS).
Figure 2 Tertiary lymphoid structures in oral squamous cell carcinoma. The pictures show representative immunohistochemical stainings
on consecutive sections of the same oral squamous cell carcinoma (OSCC) tissue sample for detection of classical tertiary lymphoid structures
(TLSs). A section that presents clusters of CD20+ B-cells (A) typically shows organized accumulations of follicular dendritic cells (FDCs) in a consecutive
section stained for CD21 (B). T-cell areas within and around the B-cell follicle are found by staining another consecutive section for CD3
(C). High-endothelial venules (HEVs) adjacent to the B-cell follicle are detected when staining a consecutive section for PNAd, as shown in
(D). CD20+, CD21+ and CD3+ cells as well as PNAd + vessels are stained brown, and cell nuclei are stained blue by hematoxylin. Germinal
centres are labelled “GC” and stroma surrounding the TLS is labelled “S” in the micrographs. Scale bars indicate 40 μm.
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Figure 3 Classical and non-classical tertiary lymphoid structures. The pictures show representative immunohistochemical stainings on
consecutive sections of two different oral squamous cell carcinoma (OSCC) tissue samples (A/C vs. B/D) for detection of classical (A/C) and non-classical
(B/D) tertiary lymphoid structures (TLSs). B-cell follicles of classical TLSs normally comprise contiguous meshworks of CD21+ follicular dendritic cells (FDCs),
as indicated in (A), and show distinct accumulations of germinal centre (GC) B-cells when staining a consecutive section for BCL6, as presented in
(C). B-cell follicles of non-classical TLSs usually contain scattered FDCs, as shown in (B; arrows), and lack GC B-cells on a consecutive section stained for
BCL6 (D). In some cases, non-classical TLSs also show abnormal GCs with BCL6+ cells dispersed throughout the follicle (data not shown). CD21+ and
BCL6+ cells are stained brown, and cell nuclei are stained blue by hematoxylin. Scale bars indicate 40 μm.
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cally significant, the majority of TLSs were found in pa-
tients with well-differentiated tumours. Further, there
were more TLSs in T1 and T2 tumours compared to
T3/T4 tumours. TLSs showed no statistically significant
association with the other variables examined. The prog-
nostic value of various clinicopathological variables in
OSCC was investigated in univariate analysis using the
log-rank test (Table 3). Based on the assessment of one
tissue level, TLS-positive tumours indicated a trend to-
ward improved survival. When the assessment of TLSs
was based on multiple tissue levels, a significant associ-
ation between the presence of TLSs and favourable out-
come in OSSC patients was found, as shown in Figure 4.
As patients presented various TLS subtypes (either clas-
sical, non-classical or both classical and non-classical),
we analysed whether the TLS subtype influenced 5-year
DSD. As presented in Additional file 1: Table S1, there
was a tendency towards lower 5-year DSD for all pa-
tients with TLSs, regardless of the subtype. However, the
differences were not statistically significant. Presence
of classical TLSs alone or in combination with non-
classical TLSs seemed to be associated with better prog-
nosis compared to the presence of only non-classicalTLSs, but again, no statistical significant difference
between the subtypes was found (P = 0.304; data not
shown). Furthermore, our results also confirmed the
prognostic value of the T, N and M stages. The variables
that showed statistically significant association with DSD
in the univariate analyses (T, N stage and TLS) were en-
tered into multivariate Cox regression analyses. The M
status was excluded from multivariate analyses as there
was only one M + patient. Proportional hazards assump-
tions were satisfied for multivariate analyses as shown by
parallel curves for different categories of prognostic
variables on log-minus-log plots (Additional file 1:
Figure S1). In multivariate analyses, only the T status
remained independently associated with disease-specific
death (P < 0.001, Table 4).
Discussion
In the present study, we have demonstrated TLSs in
OSCC by immunohistochemical analyses. To the best of
our knowledge, this is the first report of TLSs in OSCCs.
TLSs were found in 16% of the patients when a single
level of the tumour was assessed, and in 21% of the pa-
tients when multiple levels of the tumours were ana-
lysed. This is a rather low occurrence compared to what
Table 3 Clinicopathologic variables as predictors for
5-year disease-specific death in univariate analysis for 80
patients with OSCC






Male 46 (57.5) 37.0 0.403
Female 34 (42.5) 29.4
Age at diagnosis, years
0-59 29 (36.3) 31.0 0.637
≥ 60 51 (63.8) 35.3
Smoking history
Never smoker 18 (22.5) 27.8
Former smoker 11 (13.8) 27.3 0.897
Current smoker 45 (56.3) 37.3
Unknown 6 (7.5) 33.3
Alcohol consumption
Never 13 (16.3) 23.1
≤ 1 times weekly 30 (37.5) 33.3 0.633
> 1 times weekly or daily 20 (25.0) 35.0
Unknown 17 (21.3) 41.2
Tumour site
Mobile tongue 38 (47.5) 21.1
Floor of mouth 22 (27.5) 40.9 0.074
All others* 20 (25.0) 50.0
Tumour differentiation
Well 30 (37.5) 26.7
Moderate 44 (55.0) 36.4 0.296
Poor 6 (7.5) 50.0
T stage**
T1 29 (36.7) 20.7
T2 27 (34.2) 11.1 <0.001
T3, T4 23 (29.1) 78.3
N stage
N0 54 (67.5) 22.2
N+ 20 (25.0) 70.0 <0.001
Unknown 6 (7.5) 16.7
M stage
M0 74 (92.5) 33.8
M+ 1 (1.3) 100.0 0.021
Unknown 5 (6.3) 20.0
HPV/p16
Negative 68 (85.0) 35.3
Positive 6 (7.5) 16.7 0.720
Unknown 6 (7.5) 33.3
TLS single level
Table 3 Clinicopathologic variables as predictors for
5-year disease-specific death in univariate analysis for 80
patients with OSCC (Continued)
Negative 67 (83.8) 37.3 0.156
Positive 13 (16.3) 15.4
TLS multiple level
Negative 63 (78.8) 39.7 0.039
Positive 17 (21.3) 11.8
P-values were calculated using the log-rank test.
*For univariate survival analysis, the tumour sites were grouped into
three categories.
**Only 79 patients were analysed because the unknown case was taken out
from the calculations.
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lung cancer, suggesting that the occurrence of TLSs var-
ies among different types of tumours [14,19,26]. When
assessed at a single level, presence of TLSs was not a sig-
nificant predictor of survival. However, when analysed at
multiple levels, their presence in the tumour was a posi-
tive prognostic factor. This indicates that the prognostic
value of TLSs depends on the type of analysis, probably
due to their rather infrequent occurrence and tumour
heterogeneity. In multivariate analyses, only T stage
turned out to be an independent prognostic factor. TLS
status, however, performed better than N stage, which
is recognized as one of the best prognostic factors in
OSCCs [4]. In the TLS-positive tumours, either single or
multiple TLSs were found in the same tissue section. In
some of the TLSs, GC B-cells and FDC meshworks wereFigure 4 Results from multiple level analysis: Kaplan Meier
analysis of 5-year disease-specific survival for 80 patients with
oral squamous cell carcinoma with and without tertiary lymphoid
structures. The presence of tertiary lymphoid structures (TLSs) is
associated with improved survival in patients with oral squamous
cell carcinoma (OSCC) (P = 0.039). The Kaplan-Meier curve shows a
5-year disease-specific survival rate of 88.2% for TLS-positive patients
and 60.3% for TLS-negative patients. The P-value was calculated
using the log-rank test.
Table 4 Results from multiple level analysis: multivariate
analysis of 5-year disease-specific death according to




T stage — — < 0.001
T stage (1) (T1 [n = 29]
v. T2 [n = 27])
0.538 0.134 - 2.151 0.381
T stage (2) (T1 [n = 29] v.
T3/T4 [n = 23])
7.237 2.814 - 18.612 < 0.001
N stage — — 0.359
N stage (1) (N0 [n = 54] v.
N + [n = 20])
1.820 0.742 - 4.461 0.191
N stage (2) (N0 [n = 54] v.
unknown [n = 5])
2.342 0.290 - 18.900 0.424
TLS (negative [n = 62] v.
positive [n = 17])
2.409 0.556 - 10.448 0.240
*Only 79 patients were analysed because the case with unknown T stage was
taken out from the calculations.
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all cells needed to generate a functional immune re-
sponse. We called lymphoid structures with defined
FDC meshworks and GCs classical TLSs, as this pheno-
type has been mostly described for TLSs in literature.
Besides the classical TLSs, we also found TLSs with dif-
fuse accumulations of FDCs and scattered or absent GC
B-cells that we termed non-classical TLSs. It remains
elusive whether non-classical TLSs have the same im-
munological properties as classical TLSs. Immunohisto-
chemistry on multiple tissue planes of the same tumour
showed in some cases that classical and non-classical
phenotypes corresponded to the same ectopic lymphoid
structure. This implies that the two different patterns
may be artefacts of the methodical approach of TLS
detection. This is also supported by the fact that both
classical and non-classical TLSs were found on the same
tissue plane. Moreover, patients with TLSs showed pro-
longed survival regardless of TLS subtype, indicating
that none of the TLS subtypes alone are particularly
associated with survival. However, we found a trend
towards better prognosis for patients with classical TLSs
or with both classical and non-classical TLSs compared
to patients with non-classical TLSs only. This indicates
that, in some cases, non-classical TLSs could also repre-
sent immature follicles that may later develop into clas-
sical TLSs with full immunogenic properties. Previous
studies have already reported the presence of fully and
not fully mature TLSs in cancer and other inflammatory
diseases [27].
Many questions about TLS development in oral cancer
remain to be elucidated. Ectopic lymphoid formation is
a common feature in chronically inflamed tissues and
has been found in a number of different diseases at vari-
ous anatomical sites [11]. After the switch from acute tochronic inflammation, gradual accumulation of lympho-
cytes as well as promotion of lymphangiogenesis and
transformation of blood vessels into lymphocyte-guiding
HEVs has been observed [28]. In oral cancer, chronically
inflamed tissue precedes most of the tumours [29], pro-
viding favourable sites for TLS formation. In our OSCC
samples, the TLSs were mainly located in the subepithe-
lial lymphocytic infiltrate close to the tumour front. It
would be of great interest to find out why the chronic
infiltrate sometimes organizes into these structures. Dis-
closing the mechanisms that regulate TLS development
may give important information on how to improve
immune-modulating cancer therapy. Lymphoid neogen-
esis has been most extensively studied in autoimmune
disorders such as rheumatoid arthritis, Sjögrens’ syn-
drome and Hashimoto’s thyroiditis, where TLSs might
contribute to disease progression [11]. In some ectopic
GCs, B-cells producing antibodies against self-antigens
have been recognized, but data are still sparse [28]. In
OSCC, it is not yet clear which antigenic targets the
lymphocytes might react to and whether auto-antigens
play a role in the induction of TLSs. In terms of viral
agents that are linked to human tumours, human papil-
lomavirus (HPV) has become a topic of interest during
the last years. While HPV is a known risk factor for oro-
pharyngeal cancer, it probably plays only a minor role in
cancers arising in the oral cavity [30]. In the present
study, there was no correlation between HPV-status and
TLS formation. Although the antigenic stimuli directing
TLS formation in OSSC are unknown, it seems likely
that the immune-modulating factors that promote TLS
development derive from the cancer cells rather than
from autoimmunity or infection. Our results show that
TLSs are most likely to form in well-differentiated tu-
mours. It has been proposed that tumour growth might
be related to stem and amplifying cell patterns, and that
dedifferentiation may play a role in the origin of cancer
stem cells (CSCs) in OSCC [31]. CSCs are a minority of
malignant cells that are thought to be able to attenuate
host anti-tumour immune responses [32]. Thus, one
could speculate that dedifferentiation makes the tumour
cells less antigenic and thereby elicits a milder inflam-
matory reaction with lower induction of TLSs. Previous
studies on lymphoid neogenesis have revealed that clear-
ance of the inflammation-inducing antigen or clinical
therapy are able to cause a complete remission of the ec-
topic lymphoid structure [9]. This might be advanta-
geous in autoimmune diseases to stop aggravation of the
disease. However, as TLSs are thought to be conducive
for patient survival in OSCC, characterization of stimu-
lating agents might be used therapeutically to promote
TLS formation by presentation of the causative agent.
Investigation of circulating lymphocytes in blood sam-
ples of OSCC patients may provide new insights into the
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ment. A long-lasting chronic inflammation, as in larger tu-
mours, could promote TLS development. In the present
study, however, more TLSs were found in smaller tumours,
clearly indicating that TLS formation can also take place in
the early phases of tumour growth.
Conclusion
We found TLS formation to be a positive prognostic fac-
tor for patients with OSSC when tumours were analysed
at multiple levels. Thus, patients with TLS-positive tu-
mours might benefit from more restrictive treatment
while a closer follow-up and more aggressive therapy
should be considered for patients with TLS-negative tu-
mours. However, before we can envisage TLSs as prognos-
tic factors in individual clinical management of OSCC
patients, larger studies on ectopic lymphoid structures are
needed. Our study shows that correct assessment of TLS
by immunohistochemistry requires careful analyses. When
assessing CD20 B-cell staining, both dense and more dif-
fuse aggregates of B-cells should be considered as putative
TLSs. We found however, that about a third of the TLS-
positive patients were missed when analysing only one level
in the tissue block. This may be due to the fact that we se-
lected blocks with representative tumour material rather
than the tumour blocks with most intense inflammation.
By selecting differently, the chance of discovering TLSs
on a single tissue level might have increased. PCR-based
approaches, such as combining analyses of a combination
of mature FDC markers, HEV markers and TLS associated
chemokines such as CCL19, CCL21 and CXCL13 [21],
could also decrease the chance of missing TLS-positive tu-
mours. Furthermore, analyses of TLS associated chemo-
kines in serum from cancer patients could be a possible
indicator of TLS formation.
The future trend in clinical cancer management points
to personalized treatment. The use of biomarkers to
guide treatment decisions along with development of
immunotherapy may benefit the patient. Thus, under-
standing TLS formation in OSCC might help to guide
targeted anti-cancer therapies and improve the dismal
survival rates of patients with oral cancer.
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